X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs STERLING BIOTECH - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD STERLING BIOTECH BIOCON LTD/
STERLING BIOTECH
 
P/E (TTM) x 75.1 -1.8 - View Chart
P/BV x 7.1 0.1 10,024.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   STERLING BIOTECH
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
STERLING BIOTECH
Dec-13
BIOCON LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,16211 11,065.7%   
Low Rs4833 14,191.2%   
Sales per share (Unadj.) Rs194.626.8 725.8%  
Earnings per share (Unadj.) Rs34.4-15.0 -230.0%  
Cash flow per share (Unadj.) Rs48.3-5.5 -883.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.954.9 440.7%  
Shares outstanding (eoy) m200.00267.87 74.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.20.3 1,630.0%   
Avg P/E ratio x23.9-0.5 -5,142.9%  
P/CF ratio (eoy) x17.0-1.3 -1,339.0%  
Price / Book Value ratio x3.40.1 2,684.2%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,4401,862 8,832.8%   
No. of employees `0009.21.4 682.0%   
Total wages/salary Rs m7,470547 1,366.1%   
Avg. sales/employee Rs Th4,213.95,303.3 79.5%   
Avg. wages/employee Rs Th809.0403.8 200.3%   
Avg. net profit/employee Rs Th745.2-2,959.0 -25.2%   
INCOME DATA
Net Sales Rs m38,9117,181 541.9%  
Other income Rs m1,57143 3,687.8%   
Total revenues Rs m40,4827,223 560.4%   
Gross profit Rs m9,795947 1,034.4%  
Depreciation Rs m2,7722,543 109.0%   
Interest Rs m2604,377 5.9%   
Profit before tax Rs m8,334-5,931 -140.5%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,616-1,924 -84.0%   
Profit after tax Rs m6,881-4,007 -171.7%  
Gross profit margin %25.213.2 190.9%  
Effective tax rate %19.432.4 59.8%   
Net profit margin %17.7-55.8 -31.7%  
BALANCE SHEET DATA
Current assets Rs m40,47714,335 282.4%   
Current liabilities Rs m16,78349,809 33.7%   
Net working cap to sales %60.9-494.0 -12.3%  
Current ratio x2.40.3 838.0%  
Inventory Days Days60403 14.8%  
Debtors Days Days83171 48.5%  
Net fixed assets Rs m45,07355,432 81.3%   
Share capital Rs m1,000268 373.3%   
"Free" reserves Rs m47,37713,935 340.0%   
Net worth Rs m48,37714,701 329.1%   
Long term debt Rs m21,0829,478 222.4%   
Total assets Rs m93,94273,988 127.0%  
Interest coverage x33.1-0.4 -9,312.0%   
Debt to equity ratio x0.40.6 67.6%  
Sales to assets ratio x0.40.1 426.8%   
Return on assets %7.60.5 1,517.6%  
Return on equity %14.2-27.3 -52.2%  
Return on capital %12.6-6.4 -196.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m12,9881,860 698.4%   
Fx outflow Rs m7,89925 31,735.6%   
Net fx Rs m5,0891,835 277.3%   
CASH FLOW
From Operations Rs m6,4001,719 372.4%  
From Investments Rs m-4,985-3,148 158.3%  
From Financial Activity Rs m-1,7751,426 -124.5%  
Net Cashflow Rs m-473-3 13,911.8%  

Share Holding

Indian Promoters % 40.4 33.9 119.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.0 -  
FIIs % 10.7 9.9 108.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 19.9 39.3 50.6%  
Shareholders   109,995 21,482 512.0%  
Pledged promoter(s) holding % 0.0 55.9 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 19, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS